For example, Chowdhury and colleagues have utilized a CRISPR‐Cas9 KO library to identify genes whose loss confers resistance to clinical PARP inhibition and to platinum‐based chemotherapy agents in BRCA1 null patient‐derived ovarian cancer cell lines [219]. This evidence concerns the gene PARP1 and ovarian cancer.